Latest Breaking News On - Lifetime risk of ascvd - Page 1 : comparemela.com

A panel of cardiologists discuss the key updates from the 2022 ACC Expert Consensus Decision Pathway on the role of nonstatin therapies for LDL-C lowering in the management of atherosclerotic cardiovascular disease risk.

United statesPayal kohliChristiem ballantyneKeithc ferdinandErind michosCardiology expert consensus decision pathwayBogalusa heart studyConsensus decision pathwaySouth asianLdl cCardiovascular diseaseCardiovascular riskPrimary preventionSecondary preventionHigh riskLifetime risk of ascvd